Geriatric assessment before CAR‑T or bispecific antibody therapy to predict side effects and outcomes in older adults
Official title: Pragmatic Geriatric Assessment (pGA) Before Bispecific Antibody and CAR-T-Cell Therapy (GA-ACT Trial) for the Prediction of Toxicity and Outcomes in Older Patients Scheduled for Chimeric Antigen Receptor T-Cell Therapy (CAR-T-Cell-Therapy) or Bispecific Antibody (bsAB) Treatment
Run by University of Zurich · NCT07309497 · Data updated 2026-11-12
This study will test whether a brief geriatric assessment done before CAR‑T or bispecific antibody treatment can help predict side effects and outcomes for people aged 65 and older with aggressive lymphoma or multiple myeloma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 208 (estimated) |
| Sponsor | University of Zurich Academic / other |
| Drugs / interventions | CAR-T |
| Locations | 2 sites (Bern and 1 other locations) |
| Status | Recruiting |
| Started | December 12, 2025 |
| Main results expected | December 1, 2027 |
| Study ends | February 1, 2028 |
| Registry record updated | December 30, 2025 |
| Trial ID | NCT07309497 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 65 or older who are scheduled for CAR‑T cell or bispecific antibody therapy and can give informed consent in German or French.
✕Probably not a fit
People younger than 65, those who cannot complete the geriatric assessment or cannot consent, and patients who cannot attend the participating Swiss centers are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, multicenter study enrolls patients aged 65 and older who are scheduled to receive CAR‑T cell therapy or bispecific antibody treatment. Participants complete a pragmatic geriatric assessment before treatment and investigators collect data on treatment‑related toxicities, complications, and clinical outcomes during follow‑up. The study aims to link baseline geriatric measures (for example functional status, cognition, nutrition, and comorbidities) with short‑ and long‑term tolerability and success of these therapies. Recruitment is taking place at Swiss university hospitals and records will be analyzed to identify predictors of poor outcomes.
Why it matters
Potential benefit: If successful, the assessment could help doctors identify older patients at higher risk of severe side effects so care can be personalized and supportive measures targeted.
How similar studies have gone: Geriatric assessments have shown predictive value for treatment tolerance in other cancer settings, but evidence specifically for CAR‑T and bispecific antibody therapies in older adults is limited and this approach is relatively novel in that context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * male or female patients age ≥ 65 years, * scheduled for CAR-T-cell or bsAB treatments * signed informed consent * sufficient knowledge of the German or French language Exclusion Criteria: * inability to understand or sign informed consent * refuse to consent
Where it's running
-
Inselspital Bern
Bern, Switzerland Recruiting -
Universitätsspital Zürich
Zurich, Switzerland Recruiting
Study contacts
- Principal investigator: Wiebke Rösler, Dr. med. — Universitätsspital Zürich
- Study coordinator: Wiebke Rösler, Dr. med.
- Email: wiebke.roesler@usz.ch
- Phone: +4144 255 11 11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.
-
Cognitive changes after BCMA CAR-T in multiple myeloma
This study tests whether cognitive function changes over time in adults with relapsed or refractory multiple myeloma who receive BCMA CAR-T therapy.
-
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.
-
Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T
This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.
-
CD7 CAR T-Cell Therapy for T-Cell Lymphomas
This study is testing a new CAR T-cell therapy for people with T-cell lymphomas that haven't responded to regular treatments to see if it is safe and effective.
-
Using golcadomide and rituximab to prepare patients for CAR T-cell therapy in aggressive B-cell lymphoma
This study is testing if a combination of golcadomide and rituximab can help patients with aggressive B-cell lymphoma get ready for CAR T-cell therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.